Emergency FMD Serotype O Vaccines Protect Cattle against Heterologous Challenge with a Variant Foot-and-Mouth Disease Virus from the O/ME-SA/Ind2001 Lineage.
cattle
foot-and-mouth disease virus
heterologous challenge
serotype O/ME-SA/Ind2001 variant
vaccine efficacy
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
29 Sep 2021
29 Sep 2021
Historique:
received:
21
08
2021
revised:
21
09
2021
accepted:
21
09
2021
entrez:
26
10
2021
pubmed:
27
10
2021
medline:
27
10
2021
Statut:
epublish
Résumé
Vaccination is one of the best approaches to control and eradicate foot-and-mouth disease (FMD). To achieve this goal, vaccines with inactivated FMD virus antigen in suitable adjuvants are being used in addition to other control measures. However, only a limited number of vaccine strains are commercially available, which often have a restricted spectrum of activity against the different FMD virus strains in circulation. As a result, when new strains emerge, it is important to measure the efficacy of the current vaccine strains against these new variants. This is important for countries where FMD is endemic but also for countries that hold an FMD vaccine bank, to ensure they are prepared for emergency vaccination. The emergence and spread of the O/ME-SA/Ind-2001 lineage of viruses posed a serious threat to countries with OIE-endorsed FMD control plans who had not reported FMD for many years. In vitro vaccine-matching results showed a poor match (r
Identifiants
pubmed: 34696216
pii: vaccines9101110
doi: 10.3390/vaccines9101110
pmc: PMC8537456
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Meat and Livestock Australia
ID : P.PSH.0779
Organisme : Department of Agriculture, Water and the Environment
ID : RRND4P-15-02-032
Références
Virus Res. 2003 Jan;91(1):47-63
pubmed: 12527437
J Mol Evol. 1995 Apr;40(4):362-71
pubmed: 7769613
Vaccine. 2015 Jun 4;33(24):2778-85
pubmed: 25917677
Prev Vet Med. 2012 Nov 1;107(1-2):27-40
pubmed: 22749763
Vaccine. 1999 Apr 9;17(15-16):1858-68
pubmed: 10217583
Vet Microbiol. 2004 Jan 14;98(1):29-36
pubmed: 14738779
Transbound Emerg Dis. 2011 Aug;58(4):291-304
pubmed: 21366894
Risk Anal. 2008 Apr;28(2):303-9
pubmed: 18419650
Vet Rec. 2008 Jun 7;162(23):753-4
pubmed: 18540035
Vaccine. 2017 Sep 12;35(38):5179-5185
pubmed: 28789849
Vaccine. 2008 Mar 20;26(13):1681-7
pubmed: 18313814
Vaccine. 2015 Aug 26;33(36):4513-9
pubmed: 26192355
Transbound Emerg Dis. 2015 Aug;62(4):388-406
pubmed: 24131661
Transbound Emerg Dis. 2016 Oct;63(5):e431-5
pubmed: 25483996
Transbound Emerg Dis. 2017 Feb;64(1):31-36
pubmed: 25754249
Transbound Emerg Dis. 2018 Feb;65(1):e104-e112
pubmed: 28856846
Vaccine. 2017 May 9;35(20):2761-2765
pubmed: 28396208
Vet Microbiol. 2004 Nov 15;103(3-4):151-60
pubmed: 15504586
Transbound Emerg Dis. 2021 Apr 29;:
pubmed: 33915027
Arch Gesamte Virusforsch. 1968;23(3):227-35
pubmed: 5680590
Vaccine. 1994 May;12(7):592-600
pubmed: 8085375
Prev Vet Med. 2012 Nov 1;107(1-2):41-50
pubmed: 22726463
Prev Vet Med. 2013 Nov 1;112(3-4):161-73
pubmed: 23958457
Vaccine. 2007 Jan 4;25(2):327-35
pubmed: 16949184
Rev Sci Tech. 2011 Apr;30(1):189-206
pubmed: 21809764
Microbiol Resour Announc. 2020 Apr 30;9(18):
pubmed: 32354972
Front Vet Sci. 2018 Jul 27;5:174
pubmed: 30101147
Res Vet Sci. 1976 Mar;20(2):142-7
pubmed: 178035
J Virol Methods. 2003 Oct;113(1):35-41
pubmed: 14500125
Vaccine. 2015 Jan 9;33(3):422-9
pubmed: 25483241
Vaccines (Basel). 2020 Feb 10;8(1):
pubmed: 32050709